Drug intelligence / Profile preview

Zhilou Xunxi

Development stage: Unknown
Lead developer: Suzhou Zhongyao Pharmaceutical Group
Modality: Small Molecules
Administration: Topical

Overview

Zhilou Xunxi is a Traditional Chinese Medicine (TCM) formulation developed by Suzhou Zhongyao Pharmaceutical Group, primarily indicated for the treatment of mixed hemorrhoids. It is formulated as granules intended for external use via fumigation and washing (Xunxi) of the perianal area. The drug is specifically used to relieve symptoms such as pain, swelling, and bleeding associated with hemorrhoids, and is frequently employed in post-operative care following hemorrhoidectomy to promote wound healing and reduce inflammation. Its pharmacological action is attributed to its herbal constituents, which provide anti-inflammatory, analgesic, and astringent effects.

Brand names: Zhilou Xunxi
Other names: Zhilou Xunxi KejiZhilou Xunxi Granules痔瘘熏洗颗粒

Beyond the preview

Go deeper on Zhilou Xunxi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhilou Xunxi.

Explore the full profile